🇺🇸💊 Trump’s Big Obesity Drug Deal: Affordable Health Breakthrough or Political Flex?
Former President Donald Trump just struck a major deal with pharma giants Eli Lilly and Novo Nordisk to slash obesity drug prices for millions of Americans. 💥
✨ What’s Changing:
Prices for popular weight-loss drugs like Wegovy and Zepbound will drop by up to 74% — from over $500/month down to $245–$350/month, and even $149/month once oral versions hit the market. 💸
Medicare will now cover some obesity treatments with co-pays around $50/month, marking a big win for older Americans. 👵🏽👴🏼
The move aims to expand access and align U.S. drug prices closer to international levels. 🌍
⚠️ But Not All Smooth Sailing:
Some Americans may still face hurdles — strict eligibility rules, insurance limitations, and uncertain rollout timelines. ⏳
Critics warn the plan could cost taxpayers billions if demand surges. 💰
❤️ Why It Matters:
With over 40% of U.S. adults obese, this could be a game-changer for public health — and a political win for Trump’s administration ahead of 2026. 🗳️